The relationship and clinical significance of secretory phospholipase A2 and lysophosphatidic acid in multiple sclerosis
10.3760/cma.j.jssn.1673-4904.2016.11.001
- VernacularTitle:分泌型磷脂酶A2、溶血磷脂酸与多发性硬化相关性研究及临床意义
- Author:
Dongxiao JIANG
;
Yanfen LIAN
- Publication Type:Journal Article
- Keywords:
Multiple sclerosis;
Secretory phospholipase A2;
Lysophosphatidic acid
- From:
Chinese Journal of Postgraduates of Medicine
2016;39(11):961-964
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the levels of secretory phospholipase A2 (sPLA2) and lysophosphatidic acid (LPA) in blood and cerebrospinal fluid of patients with multiple sclerosis (MS), and to explore the relationship between the levels of these inflammatory biomarkers and disease activity of MS. Methods Blood samples were collected from 21 MS patients of acute period (acute period of MS group), 20 MS patients of remitting period (remitting period of MS group) and 21 patients with non inflammatory and vascular neurologic disease (control group). The levels of sPLA2 and LPA in blood and cerebrospinal fluid were measured and compared. Results The levels of sPLA2 and LPA in blood and cerebrospinal fluid before treatment in acute period of MS group were significantly higher than those in remitting period of MS group (P<0.01) and in control group (P<0.01). The levels of sPLA2 and LPA in blood and cerebrospinal fluid after treatment were significantly lower than those before treatment in acute period of MS group (P<0.01). The levels of sPLA2 and LPA in blood before and after treatment had correlations in acute period of MS group (r=0.962, P=0.000;r=0.848, P=0.000). The levels of sPLA2 and LPA in cerebrospinal fluid before and after treatment had correlations in the acute period group (r=0.968, P=0.000;r=0.850, P=0.000). Conclusions The levels of sPLA2 and LPA in blood and cerebrospinal fluid may be used as inflammatory biomarkers for disease activity in MS patients.
